Retension Pharmaceuticals (NASDAQ:RTSN) Research Coverage Started at Zacks Research

Zacks Research began coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a research report released on Wednesday morning,Zacks reports. The firm issued a hold rating on the stock.

Other analysts have also issued reports about the stock. Guggenheim began coverage on shares of Retension Pharmaceuticals in a research report on Monday, November 2nd. They set a “buy” rating and a $55.00 price target on the stock. Oppenheimer assumed coverage on shares of Retension Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price objective for the company. Finally, Leerink Partners assumed coverage on shares of Retension Pharmaceuticals in a research note on Tuesday. They set a “strong-buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Retension Pharmaceuticals currently has an average rating of “Buy” and an average target price of $52.50.

Retension Pharmaceuticals Price Performance

Shares of NASDAQ RTSN traded up $0.32 during trading hours on Wednesday, hitting $11.04. The company had a trading volume of 29,421 shares, compared to its average volume of 150,751. Retension Pharmaceuticals has a 1-year low of $9.66 and a 1-year high of $18.64.

Insider Activity at Retension Pharmaceuticals

In other Retension Pharmaceuticals news, Director Franklin Berger bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, with a total value of $120,000.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at $120,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric Keller bought 20,800 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the completion of the acquisition, the chief executive officer directly owned 423,377 shares in the company, valued at $5,080,524. The trade was a 5.17% increase in their position. The SEC filing for this purchase provides additional information.

About Retension Pharmaceuticals

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.